IXICO plc has completed a placing, subscription and retail offer
IXICO plc has raised US$5 million (£4.05 million) through an over-subscribed placing, subscription and retail offer, issuing 42,621,508 new ordinary shares at 9.5 pence per share, a premium to the price at the time. This important fundraising initiative enables the company to further its pioneering work in neuroscience through advanced imaging and data analytics.
IXICO is a leading medical imaging services provider, specializing in supporting clinical trials for pharmaceutical and biotech companies. With a global network of imaging sites and its custom TrialTracker platform, IXICO offers advanced imaging analytics and digital biomarker services for a variety of neurological diseases, including Alzheimer’s, Huntington’s, Parkinson’s and rare neurological disorders. The company is committed to regulatory compliance and has extensive experience in early-phase clinical development and extended longitudinal studies.
Oaklins Cavendish, one of Oaklins’ member firms in the UK, advised IXICO plc on this transaction.
Talk to the deal team
Related deals
CustomerXPs Software (Clari5) has been acquired by Perfios Software Solutions
Bengaluru-based SaaS firm Perfios Software Solutions Private Ltd. has acquired 100% of the equity shares in the fraud-detection platform CustomerXPs Software Private Ltd. (Clari5) for an undisclosed amount, enhancing its anti-financial crime management suite for financial institutions.
Learn moreDimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Learn moreAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn more